Business Description
OncoCyte Corp
NAICS : 541380
SIC : 8734
ISIN : US68235C1071
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.84 | |||||
Equity-to-Asset | 0.14 | |||||
Debt-to-Equity | 0.41 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -8.05 | |||||
Beneish M-Score | -5.56 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -19.2 | |||||
3-Year EBITDA Growth Rate | 31.3 | |||||
3-Year EPS without NRI Growth Rate | 34 | |||||
3-Year FCF Growth Rate | 28.1 | |||||
3-Year Book Growth Rate | -36.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | 25.37 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 16.08 | |||||
9-Day RSI | 24.19 | |||||
14-Day RSI | 28.42 | |||||
6-1 Month Momentum % | 2.26 | |||||
12-1 Month Momentum % | 4.63 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.53 | |||||
Quick Ratio | 0.5 | |||||
Cash Ratio | 0.37 | |||||
Days Inventory | 102.77 | |||||
Days Sales Outstanding | 290.46 | |||||
Days Payable | 435.87 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -33.7 | |||||
Shareholder Yield % | -0.54 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -16.22 | |||||
Operating Margin % | -3226.94 | |||||
Net Margin % | -6085.19 | |||||
FCF Margin % | -2832.86 | |||||
ROE % | -211.42 | |||||
ROA % | -57.93 | |||||
ROIC % | -32.75 | |||||
ROC (Joel Greenblatt) % | -731.88 | |||||
ROCE % | -64.77 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 29.2 | |||||
PB Ratio | 2.98 | |||||
EV-to-EBIT | -0.88 | |||||
EV-to-EBITDA | -0.91 | |||||
EV-to-Revenue | 53.36 | |||||
EV-to-Forward-Revenue | 9.99 | |||||
EV-to-FCF | -1.87 | |||||
Earnings Yield (Greenblatt) % | -113.64 | |||||
FCF Yield % | -54.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OCX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
OncoCyte Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.709 | ||
EPS (TTM) ($) | -4.54 | ||
Beta | 1.59 | ||
Volatility % | 53.72 | ||
14-Day RSI | 28.42 | ||
14-Day ATR ($) | 0.151534 | ||
20-Day SMA ($) | 2.342 | ||
12-1 Month Momentum % | 4.63 | ||
52-Week Range ($) | 1.98 - 3.82 | ||
Shares Outstanding (Mil) | 16.84 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
OncoCyte Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
OncoCyte Corp Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
OncoCyte Corp Frequently Asked Questions
What is OncoCyte Corp(OCX)'s stock price today?
When is next earnings date of OncoCyte Corp(OCX)?
Does OncoCyte Corp(OCX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |